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Over the past several years, genome-wide association studies
(GWAS) have successfully identified genetic loci strongly
associated with bipolar disorder (BP).1–3 Some of the most
consistent findings have been in variants located in the ANK3
(ankyrin-G) gene located on chromosome 10q. Schultz et al.4
found that BP risk alleles in ANK3, rs9804190 and
rs10994336, contributed independently to BP with no signi-
ficant marker–marker interaction. Subsequent association
studies support the ANK3 association in other populations of
primarily European or Asian ancestries.5,6 To date, no studies
have been reported that focus in Latino populations.
To evaluate the role of ANK3 in the Latino population, we
have designed a family-based association study to evaluate
single-nucleotide polymorphisms (SNPs) spanning the ANK3
gene, including GWAS-significant SNPs rs9804190 and
rs10994336, in 215 Latino pedigrees with reported ancestry
from Mexico or Central America. Inclusion criteria required a
proband with a bipolar disorder type I (BPI) diagnosis with at
least one sibling with a clinical diagnosis of BPI or
schizoaffective bipolar disorder (SABP), and a minimum of
two additional first-degree relatives willing to participate.
Additional family members with a history of affective or
psychotic disorders were included when possible. The sample
consisted of 157 case–parent trios and 258 affected subjects
with one parent genotyped. All study participants were
diagnosed using Diagnostic and Statistical Manual of
Mental Disorders (DSM)-IV criteria using a best-estimation
consensus procedure as previously described.7 Of the
929 individuals in this study, 466 were diagnosed with BPI
and 16 were diagnosed with SABP.
DNA was isolated from lymphoblastoid cell lines. SNP
selection covering the ANK3 gene was based on a tagging
SNP approach (r2X0.9) using the SNPbrowser software
version 4.0.1 (Life Technologies Corporation, Carlsbad, CA,
USA). Known BP risk variants in ANK3, rs9804190 and
rs10994336, were included in the panel as well as additional
proximal SNPs to these known variants. A total of 38 SNPs
were genotyped using a custom-designed Illumina GoldenGate
SNP assay (Illumina, San Diego, CA, USA). After assessment
of quality control, a total of 36 SNPs for 213 pedigrees (913
individuals) were retained for statistical analysis.
Analyses of individual SNPs and haplotypes were com-
pleted with the Family Based Association Test (FBAT) version
2.0.3,8 using an additive genetic model (Table 1). We were
unable to replicate associations of the BP risk variants
rs9804190 and rs10994336 in our dataset. To thoroughly test
the loci identified by the two individual SNPs previously
reported to be associated with BP, Haploview version 4.2
(http://www.broadinstitute.org/haploview/haploview)9 was
used to visualize linkage disequilibrium (LD) relationships
between all genotyped variants (36 SNPs) within and
surrounding the ANK3 region and to construct LD blocks
following the D0 method described by Gabriel et al.10 Five
SNPs were found to be in high LD with rs10994336. SNPs
Table 1 Family-based association tests for ANK3 variants and haplotypes under additive model
Marker Over-transmitted Allele frequency Z-score P-value Adjusted P-valuea
rs1380455 T 0.728 2.108 0.035 0.193
rs16914968 T 0.076 1.643 0.100 0.470
rs1551684 C 0.914 1.111 0.267 0.844
rs3808942 T 0.745 0.094 0.925 1.000
rs3808943 T 0.311 2.430 0.015 0.087
rs10994336 T 0.310 1.939 0.053 0.276
Haplotype Informative families Haplotype frequency Z-score P-value Permutation P-valueb
TCCTTT 103 0.315 2.266 0.023 0.035*
GCCTCC 111 0.279 1.572 0.116 0.126
TCCCCC 100 0.247 0.565 0.572 0.552
TCTTCC 43 0.070 0.778 0.436 0.396
TTCTCC 39 0.069 1.737 0.082 0.079
Abbreviation: ANK3, ankyrin-G.
aBonferroni-adjusted P-values. bP-values derived from 10 000 permutations; *denotes statistical significance.
Non-adjusted P-valueso0.05 are in bold.
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rs1380455 and rs3808943 were nominally associated with
BP; however, the associations did not meet the Bonferroni
threshold of significance (P¼ 0.008). No other genotyped
SNPs were in high LD with the rs9804190 risk allele and were
therefore dropped from further analysis. Haplotype analyses
were performed on the six-locus haploblock encompassing
the rs10994336 BP risk variant. The TCCTTT haplotype
showed an over-transmission in BP, which was statistically
significant after permutation test with 10 000 simulations.
Interestingly, the rs10994336 (T) BP risk allele was also
present in the TCCTTT haplotype showing increased risk
(Z¼ 2.266, permuted P¼ 0.035). The whole marker permuta-
tion test was also significant (P¼ 0.022).
In closing, we attempted to validate in nearly 1000 Latinos
the significant ANK3 variants associated with BP identified in
populations of predominantly European ancestry. The asso-
ciations between previous reported genetic variants of ANK3
(rs9804190 and rs10994336) and risk of BP were not
significant in individual SNP analysis on our population.
However, a six-locus ANK3 haplotype encompassing the
rs10994336 risk allele was significantly associated with BP.
This suggests that the rs10994336 risk allele associated with
BP in European and Asian ancestry populations is also part of
a more specific haplotype associated with BP in Latino
populations. Targeted sequencing within these haploblock
regions will be helpful in identifying the true functional variants
in ANK3 that underlie BP. These results provide additional
evidence thatANK3 is associated with BP and provide the first
evidence that variations in this gene might have a role in the
pathogenesis of this disorder in the Latino population.
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